Our Portfolio

Mission: At ProNeurogen, we are deeply committed to improving the lives of patients with vascular dementia by developing new therapies with the potential to slow the progression of disease, and help individuals maintain healthy brains for life.

Vision: To be the global leader in protecting brain health of millions by developing life-changing therapies to treat cognitive impairment associated with neurodegenerative diseases.

ProNeurogen, founded in 2013, is a spin-out of the medical research program at the University of Arizona. The technology is licensed to ProNeurogen per an exclusive license agreement.

ProNeurogen uses a lean biotech model whereby the development of the technology is supported by expertise from several outside consultants and service providers in pharmaceutical R&D, medicinal formulations, clinical trial management, medication delivery, FDA regulatory processes, etc.